The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
| Autor: | Crommelin, Daan Ja, Broich, Karl, Holloway, Chris, Meesen, Bianca, Lizrova Preiningerova, Jana, Prugnaud, Jean-Louis, Silva-Lima, Beatriz, Sub General Pharmaceutics, Pharmaceutics |
|---|---|
| Přispěvatelé: | Sub General Pharmaceutics, Pharmaceutics |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Drug
safety medicine.medical_specialty Immunologic Factors media_common.quotation_subject Regulator Pharmacology multiple sclerosis 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Stakeholder Participation medicine Drug approval Humans Interdisciplinary communication Cooperative Behavior Intensive care medicine generics Drug Approval media_common Quality Indicators Health Care Biosimilars non-biological complex drugs (NBCDs) business.industry Multiple sclerosis follow-on products Biosimilar Drugs Investigational medicine.disease Quality Improvement Treatment Outcome Neurology Interdisciplinary Communication Neurology (clinical) Cooperative behavior non-biological complex drugs (NBCDs) safety business 030217 neurology & neurosurgery |
| Zdroj: | Multiple sclerosis (Houndmills, Basingstoke, England), 22(2 Suppl), 47. SAGE Publications Ltd |
| ISSN: | 1352-4585 |
| Popis: | Background: Although there is still no cure for multiple sclerosis (MS), the introduction of several innovative drugs with modes of action different from that of the existing drug arsenal and the progress in monitoring disease progression by imaging and using biomarkers are currently causing a knowledge surge. This provides opportunities for improving patient disease management. New therapies are also under development and pose challenges to the regulatory bodies regarding the optimal design of clinical trials with more patient-focused clinical endpoints. Moreover, with the upcoming patent expiry of some of the key first-line MS treatments in Europe, regulatory bodies will also face the challenge of recommending marketing authorisation for generic and abridged versions based on appropriate requirements for demonstrating equality/similarity to the innovator’s product. Objective: The goal of this article is to improve the understanding of the relevant guidance documents of the European Medicines Agency (EMA) on clinical investigation of medicinal products and to highlight the issues that the agency will need to clarify regarding follow-on products of first-line MS treatments. Conclusion: Today, it is clear that close collaboration between patients, healthcare professionals, regulatory bodies and industry is crucial for developing new safe and effective drugs, which satisfy the needs of MS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|